EuroMEEting - Genetic Alliance UK

Lunch
Lunch
23RD ANNUAL EUROMEETING AT A GLANCE
51
Monday, 28 March 2011
Pre-Conference Tutori
Plenary 14:0
La Grande Reception Networki
Theme 6 Theme 7 Theme 8 Theme 9 Theme 10 Theme
Engaging the Research
World! Pre-Clinical
Research and Development
Statistics across the
Drug Lifecycle
Developing Medicines for
Special Populations
Pharma e-World
CMC, Inspection and
Assessment, Quality and
Counterfeiting
The Drug/D
Boundary: Is It
Disappe
Tuesday, 29 March 2011
Session 0601
International Strategy for
Non-Clinical Consultants
Session 0101/0701
Trial Design and Interpretation
for Personalised Medicine-
Delivering C21 Drug
Development
Session 0801
Increasing Global Regulatory
Dialogue
Session 0901
Use of Electronic Health
Records for Clinical Research
Session 1001
Development of
Pharmaceutical Products in the
Context of the New
Quality Paradigm
Session 1
Keynote Introd
Setting the
Coffee B
Session 0602
Non-Clinical Evaluation of
Drug-Induced Hepatotoxicity
Session 0702
Using Indirect Comparisons in
Assessment of Clinical Data
Session 0802
Will Modelling and Simulation
Accelerate Drug Development
for Children?
Session 0902
New Approaches to
Pharmacovigilance when
Employing Electronic Health
Records (EHRs)
Session 1002
New Paradigm, Latest
Development (2): Interaction
and implementation of
ICH Q8, Q9 and Q10
Session 1
Borderline Prod
Impact on Dev
Session 0603/1303
Safety Aspects in the
Development of Vaccines
Session 0703
Recent Developments in
Software Solutions for
Adaptive Trial Designs
Session 0803
Can Bridging and Extrapolation
of Data Reduce the Number
of Clinical Trials?
Session 0903
Comparing ePRO Technologies:
What works?
Session 1003
Variation Regulation:
Post approval change
management protocol
Session 1
Regulatory Fram
Combination P
Coffee B
Session 0604
Biobanking: Logistics and
samples handling
Session 0704
Common Issues at SAWP
(Scientific Advice
Working Party)
Session 0804
Risk Management for
Special Populations
Session 0904
Data Privacy in the
Pharma e-World
Session 1004
Is There a Need for a
Pharmacopoeia in the New
Quality Paradigm?
Session 010
In Vitro Diag
Wednesday, 30 March 2011
Networking Recept
Session 0605
Non-Clinical Aspects of
First-In-Humans
Session 0705
Quantitative Approach for
Benefit/Risk – Challenges
and Opportunities
Session 0805
Challenges and Opportunities
to Develop Suitable
Formulations
Session 0905
Practical Implementation of
the CDISC Standards
Session 1005
Globalisation of Medicine (1):
Impact on Quality
Session 1
Points to Conside
Development of C
Produc
Coffee B
Session 0606
Biomarkers in Non-Clinical
Safety Assessment
Session 0706
Communicating Complex
Statistical Results
Session 0806
Medicines for Geriatric Patients
Session 0906
Using Technology to Improve
the Clinical Trial Process
Session 1006
Globalisation of Medicine (2):
Counterfeiting Aspects
Session 1
Development o
Device
Session 0607
The Non-Clinical Development
of Anti-Cancer Pharmaceuticals
Session 0707/0907
Statistical Computing: Progress
in Computational Science in
Clinical Trials
Session 0807/1307
How Should the Paediatric
Scheme be Amended
and Why?
Session 0707/0907
Statistical Computing: Progress
in Computational Science in
Clinical Trials
Session 1007
Paediatric Formulation
Session 1
Clinical Develo
Medical De
Session 0608
Contemporary Issues in
Non-Clinical Development
of Biotechnology-Derived
Products
Session 0708
Subgroup Analyses
Session 0808
Medicines for Pregnant and
Lactating Women
Session 0908
Clinical Trial Technologies and
the Site: Where next?
Session 1008
What’s New in Quality?
Coffee B
End of Conf